Pulmonary Arterial Hypertension and Systemic Sclerosis Relation: A Single Centre Experience

Heart Lung and Circulation

Volumn 23, Issue 7, 2014, Pages 667-673

  Demir, Nalan ^a   Şahin, Ali ^b   Küçükşahin, Orhan ^b   Kayacan, Oya ^a   Dinçer, rem ^b   Sayin, Tamer ^b   Karnak, Demet ^a   Turgay, Murat ^b  

^a ANKARA UNIVERSITY   (Turkey)

^b Department of Rheumatology ^*  (Turkey)

Author keywords

Diffuse cutaneous scleroderma; Interstitial lung disease; Limited cutaneous scleroderma; Pulmonary arterial hypertension; Systemic sclerosis

Indexed keywords

6 MINUTE WALK DISTANCE; ADULT; ARTICLE; BLOOD OXYGEN TENSION; CARBON MONOXIDE DIFFUSION TEST; CARDIOPULMONARY EXERCISE TEST; DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS; DISEASE ASSOCIATION; DISEASE DURATION; ECHOCARDIOGRAPHY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEART CATHETERIZATION; HUMAN; INTERSTITIAL LUNG DISEASE; LIMITED CUTANEOUS SYSTEMIC SCLEROSIS; MAJOR CLINICAL STUDY; MALE; MEDSGER SCORE; MODIFIED RODNAN SKIN SCORE; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RATING SCALE; RETROSPECTIVE STUDY; SCORING SYSTEM; SYSTEMIC SCLEROSIS; THORAX SCINTISCANNING; AGED; CLINICAL TRIAL; COMPLICATION; HYPERTENSION, PULMONARY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; SCLERODERMA, SYSTEMIC;

ADULT; AGED; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC;

EID: 84901983458     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2014.02.002     Document Type: Article

References (38)

1. Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007, 66(7):940-944.
2. Hachulla E., Gressin V., Guillevin L., Carpentier P., Diot E., Sibilia J., Kahan A., Cabane J., Francès C., Launay D., Mouthon L., Allanore Y., Tiev K.P., Clerson P., de Groote P., Humbert M. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005, 52:3792-3800.
3. Steen V., Medsger T.A. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003, 48(2):516-522.
4. Mukerjee D., St George D., Coleiro B., Knight C., Denton C.P., Davar J., Black C.M., Coghlan J.G. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003, 62(11):1088-1093.
5. Bull T.M. Screening and therapy of pulmonary hypertension in systemic sclerosis. Current opinion in rheumatology 2007, 19(6):598-603.
6. Wells A.U., Steen V., Valentini G. Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology 2009, 48:iii40-iii44.
7. Simonneau G., Galiè N., Rubin L.J., Langleben D., Seeger W., Domenighetti G., Gibbs S., Lebrec D., Speich R., Beghetti M., Rich S., Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004, 43(12 Suppl S):5S-12S.
8. Kawut S.M., Taichman D.B., Archer-Chicko C.L., Palevsky H.I., Kimmel S.E. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003, 123(2):344-350.
9. LeRoy E.C., Medsger T.A. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001, 28(7):1573-1576.
10. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-590.
11. Medsger T.A., Bombardieri S., Czirjak L., Scorza R., Della Rossa A., Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003, 21(3):S42-S46.
12. Hudson M, Steele R, Canadian Scleroderma Research Group (CSRG), Baron M. Update on indices of disease activity in systemic sclerosis. Semin Arthritis Rheum. 2007;37(2):93-8.
13. Kovelis D., Segretti N.O., Probst V.S., Lareau S.C., Brunetto A.F., Pitta F. Validation of the Modified Pulmonary Functional Status and Dyspnea Questionnaire and the Medical Research Council scale for use in Brazilian patients with chronic obstructive pulmonary disease. J Bras Pneumol. 2008, 34(12):1008-1018.
14. Miller M.R., Crapo R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., Enright P., van der Grinten C.P., Gustafsson P., Jensen R., Johnson D.C., MacIntyre N., McKay R., Navajas D., Pedersen O.F., Pellegrino R., Viegi G., Wanger J. General considerations for lung function testing. Eur Respir J 2005, 26:153-161. ATS/ERS Task Force.
15. Macintyre N., Crapo R.O., Viegi G., Johnson D.C., van der Grinten C.P., Brusasco V., Burgos F., Casaburi R., Coates A., Enright P., Gustafsson P., Hankinson J., Jensen R., McKay R., Miller M.R., Navajas D., Pedersen O.F., Pellegrino R., Wanger J. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005, 26:720-735.
16. ATS statement; guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111-117. American Thoracic Society Committee on Proficiency Standards for Clinical Pulmonary Function, Laboratories.
17. MacDonald S.L., Rubens M.B., Hansell D.M., Copley S.J., Desai S.R., du Bois R.M., Nicholson A.G., Colby T.V., Wells A.U. Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. Radiology 2001, 221(3):600-605.
18. Goh N.S., Desai S.R., Veeraraghavan S., Hansell D.M., Copley S.J., Maher T.M., Corte T.J., Sander C.R., Ratoff J., Devaraj A., Bozovic G., Denton C.P., Black C.M., du Bois R.M., Wells A.U. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008, 177(11):1248-1254.
19. McLaughlin V.V., Archer S.L., Badesch D.B., Barst R.J., Farber H.W., Lindner J.R., Mathier M.A., McGoon M.D., Park M.H., Rosenson R.S., Rubin L.J., Tapson V.F., Varga J., Harrington R.A., Anderson J.L., Bates E.R., Bridges C.R., Eisenberg M.J., Ferrari V.A., Grines C.L., Hlatky M.A., Jacobs A.K., Kaul S., Lichtenberg R.C., Lindner J.R., Moliterno D.J., Mukherjee D., Pohost G.M., Rosenson R.S., Schofield R.S., Shubrooks S.J., Stein J.H., Tracy C.M., Weitz H.H., Wesley D.J. ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009, 119(Apr 28 16):2250-2294.
20. Yamane K., Ihn H., Asano Y., Yazawa N., Kubo M., Kikuchi K., Soma Y., Tamaki K. Clinical and laboratory features of scleroderma patients with pulmonary hypertension. Rheumatology (Oxford) 2000, 39(11):1269-1271.
21. Varga J. Systemic sclerosis: an update. Bull NYU Hosp Jt Dis 2008, 66(3):198-202.
22. Walker U.A., Tyndall A., Czirják L., Denton C., Farge-Bancel D., Kowal-Bielecka O., Müller-Ladner U., Bocelli-Tyndall C., Matucci-Cerinic M. Clinical risk assesment of organ manifestations in systemic sclerosis: a report from EULAR Scleroderma Trials and Research (EUSTAR) group database. Ann Rheum Dis 2007, 66:754-763.
23. Assassi S., Sharif R., Lasky R.E., McNearney T.A., Estrada-Y-Martin R.M., Draeger H., Nair D.K., Fritzler M.J., Reveille J.D., Arnett F.C., Mayes M.D. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther. 2010, 12(5):R166. GENISOS Study Group, Epub 2010 Sep 2.
24. Clements P.J., Roth M.D., Elashoff R., Tashkin D.P., Goldin J., Silver R.M., Sterz M., Seibold J.R., Schraufnagel D., Simms R.W., Bolster M., Wise R.A., Steen V., Mayes M.D., Connelly K., Metersky M., Furst D.E. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis. 2007, 66(12):1641-1647. Scleroderma Lung Study Group.
25. Steen V.D., Medsger T.A. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000, 43(11):2437-2444.
26. Launay D., Remy-Jardin M., Michon-Pasturel U., Mastora I., Hachulla E., Lambert M., Delannoy V., Queyrel V., Duhamel A., Matran R., De Groote P., Hatron P.Y. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 2006, 33(9):1789-1801.
27. Battle R.W., Davitt M.A., Cooper S.M., Buckley L.M., Leib E.S., Beglin P.A., Tischler M.D. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996, 110:1515-1519.
28. McGoon M., Gutterman D., Steen V., Barst R., McCrory D.C., Fortin T.A., Loyd J.E. American College of Chest Physicians. Screening, early detection and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004, 126:14S-34S.
29. Denton C.P., Cailes J.B., Phillips G.D., Wells A.U., Black C.M., Bois R.M. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 1997, 36(2):239-243.
30. Campo A., Mathai S.C., Le Pavec J., Zaiman A.L., Hummers L.K., Boyce D., Housten T., Champion H.C., Lechtzin N., Wigley F.M., Girgis R.E., Hassoun P.M. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010, 182(2):252-260.
31. Klein-Weigel P., Opitz C., Riemekasten G. Systemic sclerosis - a systematic overview: part 1 - disease characteristics and classification, pathophysiologic concepts, and recommendations for diagnosis and surveillance. Vasa 2011, 40(1):6-19.
32. Cox S.R., Walker J.G., Coleman M., Rischmueller M., Proudman S., Smith M.D., Ahern M.J., Roberts-Thomson P.J. Isolated pulmonary hypertension in scleroderma. Intern Med J 2005, 35:28-33.
33. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 2003, 62:97-99.
34. Chung L., Liu J., Parsons L., Hassoun P.M., McGoon M., Badesch D.B., Miller D.P., Nicolls M.R., Zamanian R.T. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010, 138(6):1383-1394.
35. Allanore Y., Borderie D., Avouac J., Zerkak D., Meune C., Hachulla E., Mouthon L., Guillevin L., Meyer O., Ekindjian O.G., Weber S., Kahan A. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008, 58(1):284-291.
36. Villalba W.O., Sampaio-Barros P.D., Pereira M.C., Cerqueira E.M., Leme C.A., Marques-Neto J.F., Paschoal I.A. Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. Chest 2007, 131(1):217-222.
37. Garin M.C., Highland K.B., Silver R.M., Strange C. Limitations to the 6-Minute Walk Test in Interstitial Lung Disease and Pulmonary Hypertension in Scleroderma. J Rheumatol 2009, 36:330-336.
38. Barst R.J., McGoon M., Torbicki A., Sitbon O., Krowka M.J., Olschewski H., Gaine S. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43(12 Suppl S). 40S-7S.